Association between Subfatin level and Preeclampsia: case-control study

Abstract

Preeclampsia is a progressive and pregnancy-specific disorder and it affects multiorgan systems. Although the pathophysiology of preeclampsia is still unknown, it involves both maternal and fetal/placental factors. Endothelial cell damage and impaired endothelial cell function play an important role in the development of preeclampsia. Adipokines have role in many pathophysiological processes in the body. Subfatin is a newly discovered adipokine, if dysfunctional may cause endothelial damage. In this study it was aimed to evaluate the relationship between subfatin and preeclampsia. This study was designed as prospective case-control study. Fifty-six women, 28 women with preeclampsia and 28 normotensive women who had delivered between gestational age of 37th and 41th weeks with singleton pregnancies in a tertiary reference hospital was included. ROC analysis was used to calculate the predictive value of Subfatin for preeclampsia. There was no statistically significant difference in terms of age, BMI, gravidity and parity between groups. Mean systolic (157.14±15.36 vs 113.21±6.55 mm/Hg, p < 0.001) and diastolic blood pressures (95.71±8.35 vs 73.21±5.47 mm/Hg, p < 0.001) were observed higher in case group than control group. Subfatin level of control group was found higher than case group and this difference was statistically significant (58.89±17.66 vs 31.85±16.58 ng/mL, p < 0.001). According to ROC analyzes; cutoff value of Subfatin level ≤ 43 ng/mL with 78.6% sensitivity and 71.4% specificity was found significant for case group. AUC was calculated as 0.872 (p < 0.001). Binary logistic regression analysis showed that low levels of subfatin was related with preeclampsia (Odds Ratio: 0.910, 95% CI: 0.866-0.955, p < 0.001). subfatin may be helpful in predicting preeclampsia development in pregnant women. Low levels of subfatin may be warning sign before its development.

Keywords

• adipokine
• preeclampsia
• pregnancy
• subfatin

References

1. 1. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol. 2020 Jun;135(6):1492-1495.
2. 2. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, Kenny LC, McCarthy F, Myers J, Poon LC, Rana S, Saito S, Staff AC, Tsigas E, von Dadelszen P. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022 Mar;27:148-169.
3. 3. Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N Engl J Med. 2002 Jan 3;346(1):33-8.
4. 4. Dawson LM, Parfrey PS, Hefferton D, Dicks EL, Cooper MJ, Young D, Marsden PA. Familial risk of preeclampsia in Newfoundland: a population-based study. J Am Soc Nephrol. 2002 Jul;13(7):1901-6.
5. 5. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG. 2004 Mar;111(3):200-6.
6. 6. Tsujimoto Y, Kataoka Y, Banno M, Taito S, Kokubo M, Masuzawa Y, Yamamoto Y. Association of low birthweight and premature birth with hypertensive disorders in pregnancy: a systematic review and meta-analysis. J Hypertens. 2022 Feb 1;40(2):205-212.
7. 7. Macedo TCC, Montagna E, Trevisan CM, Zaia V, de Oliveira R, Barbosa CP, Laganà AS, Bianco B. Prevalence of preeclampsia and eclampsia in adolescent pregnancy: A systematic review and meta-analysis of 291,247 adolescents worldwide since 1969. Eur J Obstet Gynecol Reprod Biol. 2020 May;248:177-186.
8. 8. Romero R, Chaiworapongsa T. Preeclampsia: a link between tropho- blast dysregulation and an antiangiogenic state. J Clin Invest 2013; 123(7): 2775–2777.

9. 9. Miao CY. Introduction: Adipokines and cardiovascular disease. Clin Exp Pharmacol Physiol. 2011;38:860–3.
10. 10. Zhu X, Zhang HW, Chen HN, Deng XJ, Tu YX, Jackson AO, et al. Perivascular adipose tissue dysfunction aggravates adventitial remodeling in obese mini pigs via NLRP3 inflammasome/IL-1 signaling pathway. Acta Pharmacol Sin. 2019;40:46–54.
11. 11. Ramsay JE, Jamieson N, Greer IA, Sattar N. Paradoxical elevation in adiponectin concentrations in women with pree- clampsia. Hypertension. 2003;42(5):891-894.
12. 12. Kajantie E, Kaaja R, Ylikorkala O, Andersson S, Laivuori H. Adiponectin concentrations in maternal serum: elevated in preeclampsia but unrelated to insulin sensitivity. J Soc Gynecol Investig. 2005;12(6):433-439.
13. 13. Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. Am J Physiol Endocrinol Metab. 2006;290(2):E326-E333.
14. 14. D’Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM. Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet Gynecol. 2005;106(2):340-344.
15. 15. Shinohara K, Wakatsuki A, Watanabe K, Ikenoue N, Fukaya T. Plasma adiponectin concentrations in women with preeclampsia. Hypertension. 2004;43(4):e17.
16. 16. Li ZY, Zheng SL, Wang P, Xu TY, Guan YF, Zhang YJ, Miao CY. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. CNS Neurosci Ther. 2014 Apr;20(4):344-54.
17. 17. Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016 May;37(5):571-9.
18. 18. Adu-Gyamfi EA, Fondjo LA, Owiredu WKBA, Czika A, Nelson W, Lamptey J, Wang YX, Ding YB. The role of adiponectin in placentation and preeclampsia. Cell Biochem Funct. 2020 Jan;38(1):106-117.
19. 19. Poston L. Leptin and preeclampsia. Semin Reprod Med. 2002 May;20(2):131-8.
20. 20. Bawah AT, Yeboah FA, Nanga S, Alidu H, Ngala RA. Serum adipocytokines and adiposity as predictive indices of preeclampsia. Clin Hypertens. 2020 Oct 1;26:19.
21. 21. Rao S, Kumari A, Sharma M, Kabi BC. Predicting Maternal Serum Adiponectin and Leptin Level as Biomarkers of Pre-eclampsia: A Prospective Study. J Obstet Gynaecol India. 2021 Feb;71(1):58-65.
22. 22. Lee JH, Kang YE, Kim JM, Choung S, Joung KH, Kim HJ, et al. Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2diabetes. Diabetes Res Clin Pract. 2018;135:7–10.
23. 23. Dadmanesh M, Aghajani H, Fadaei R, Ghorban K. Lower serum levels of Meteorin- like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One.2018;13:e0204180.
24. 24. El-Ashmawy HM, Selim FO, Hosny TAM, Almassry HN. Association of low serum Meteorin like (Subfatin) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract. 2019;150:57–63.
25. 25. Chung HS, Hwang SY, Choi JH, Lee HJ, Kim NH, Yoo HJ, et al. Implications of circulating Meteorin-like (Subfatin) level in human subjects with type 2 diabetes. DiabetesRes Clin Pr. 2018;136:100–7.
26. 26. AlKhairi I, Cherian P, Abu-Farha M, Madhoun AA, Nizam R, Melhem M, et al. Increased expression of Meteorin-Like hormone in type 2 diabetes and obesity and its association with irisin. Cells. 2019;8:1283.
27. 27. Gordon A Ferns, Kiavash Fekri, Milad Shahini Shams Abadi, Mahdi Banitalebi Dehkordi & Mohammad-Hassan Arjmand (2021): A meta-analysis of the relationship between serums metrnl-like protein/subfatin and risk of type 2 diabetes mellitus and coronary artery disease, Archives of Physiology and Biochemistry.
28. 28. Fadaei R, Dadmanesh M, Moradi N, Ahmadi R, Shokoohi Nahrkhalaji A, Aghajani H, Ghorban K. Serum levels of subfatin in patients with type 2 diabetes mellitus and its association with vascular adhesion molecules. Arch Physiol Biochem. 2020 Oct;126(4):335-340.
29. 29. Liu ZX, Ji HH, Yao MP, Wang L, Wang Y, Zhou P, et al. Serum Metrnl is associated with the presence and severity of coronary artery disease. J Cell Mol Med. 2019;23:271–80. 10.1111/jcmm.13915
30. 30. Yilmaz M, Cagri Goktekin M, Ilhan N. Subfatin concentration decreases in acute coronary syndrome. Biochem Med (Zagreb). 2022 Jun 15;32(2):020704.
31. 31. Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, Puig R, Martinez E, Moreno P, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int J Obes (Lond). 2018;42:919–22.